LillyDirect Foundayo Review
Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
High confidence · Last verified 2026-04-07 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
LillyDirect Foundayo is one of the most affordable GLP-1 options on the market.
Score Breakdown
Drugs Offered
LillyDirect Foundayo prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Foundayo (Lilly Savings Card) | brand | $25 |
| Foundayo (cash, starting dose) | brand | $149 |
| Foundayo (cash, higher doses) | brand | $299 |
✓ Pros
- •Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- •Direct from manufacturer — no compounding, no third-party reseller
- •Daily oral pill, no injections, no refrigeration
- •Available in all 50 states
✗ Cons
- •Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- •Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- •$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- •Strict empty-stomach 30-minute window may be hard for some patients to follow
Ready to start with LillyDirect Foundayo?
Starting at $25/month. See current pricing and start your free consultation.
Sources & methodology
Our LillyDirect Foundayo review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
Alternatives to LillyDirect Foundayo
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with LillyDirect Foundayo?
Starting at $25/month. See current pricing and start your free consultation.